{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:45:52Z","timestamp":1790999152662,"version":"4.1.0"},"reference-count":162,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jpsychires.2024.12.042","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T11:08:12Z","timestamp":1735384092000},"page":"716-727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Preventing disease progression in schizophrenia: What are we waiting for"],"prefix":"10.1016","volume":"181","author":[{"given":"Jeffrey A.","family":"Lieberman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Mendelsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry E.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Emsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jpsychires.2024.12.042_bib1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archgenpsychiatry.2009.192","article-title":"Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial","volume":"67","author":"Amminger","year":"2010","journal-title":"Arch. Gen. Psychiatr."},{"issue":"7","key":"10.1016\/j.jpsychires.2024.12.042_bib2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.biopsych.2011.05.017","article-title":"Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia","volume":"70","author":"Andreasen","year":"2011","journal-title":"Biol. Psychiatr."},{"issue":"6","key":"10.1016\/j.jpsychires.2024.12.042_bib3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1176\/appi.ajp.2013.12050674","article-title":"Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study","volume":"170","author":"Andreasen","year":"2013","journal-title":"Am. J. Psychiatr."},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/archpsyc.55.3.225","article-title":"Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia","volume":"55","author":"Arnold","year":"1998","journal-title":"Arch. Gen. Psychiatr."},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archpsyc.58.1.33","article-title":"Volumes of brain structures in twins discordant for schizophrenia","volume":"58","author":"Baar\u00e9","year":"2001","journal-title":"Arch. Gen. Psychiatr."},{"issue":"1\u20133","key":"10.1016\/j.jpsychires.2024.12.042_bib6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.schres.2012.06.036","article-title":"Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia","volume":"140","author":"Bartzokis","year":"2012","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/00332747.1952.11022883","article-title":"Successful outpatient psychotherapy of a chronic schizophrenic with a delusion based on borrowed guilt","volume":"15","author":"Beck","year":"1952","journal-title":"Psychiatry"},{"issue":"4","key":"10.1016\/j.jpsychires.2024.12.042_bib8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1176\/appi.ps.201600512","article-title":"OnTrackNY: the development of a coordinated specialty care program for individuals experiencing early psychosis","volume":"68","author":"Bello","year":"2017","journal-title":"Psychiatr. Serv."},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0893-133X(01)00225-1","article-title":"GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder","volume":"25","author":"Benes","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/archneur.55.3.326","article-title":"Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype","volume":"55","author":"Berg","year":"1998","journal-title":"Arch. Neurol."},{"issue":"1\u20133","key":"10.1016\/j.jpsychires.2024.12.042_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.schres.2016.03.025","article-title":"Predictors and longitudinal course of cognitive functioning in schizophrenia spectrum disorders, 10years after baseline: the OPUS study","volume":"175","author":"Bergh","year":"2016","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.jpsychires.2024.12.042_bib12","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s12325-017-0507-x","article-title":"Long-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole oce-mnthly","volume":"34","author":"Biagi","year":"2017","journal-title":"Adv. Ther."},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/archpsyc.1993.01820150074008","article-title":"Advancing a neurodevelopmental origin for schizophrenia","volume":"50","author":"Bloom","year":"1993","journal-title":"Arch. Gen. Psychiatr."},{"issue":"8","key":"10.1016\/j.jpsychires.2024.12.042_bib14","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archpsyc.1985.01790310046006","article-title":"Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage","volume":"42","author":"Bogerts","year":"1985","journal-title":"Arch. Gen. Psychiatr."},{"issue":"5\u20136","key":"10.1016\/j.jpsychires.2024.12.042_bib15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0920-9964(90)90013-W","article-title":"Post-mortem volume measurements of limbic system and basal ganglia structures in chronic schizophrenics. Initial results from a new brain collection","volume":"3","author":"Bogerts","year":"1990","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.jpsychires.2024.12.042_bib16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1503\/jpn.120007","article-title":"Abnormal synaptic pruning in schizophrenia: urban myth or reality?","volume":"37","author":"Boksa","year":"2012","journal-title":"J. Psychiatry Neurosci."},{"issue":"2","key":"10.1016\/j.jpsychires.2024.12.042_bib17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/JCP.0b013e31820e3f58","article-title":"Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia","volume":"31","author":"Boonstra","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.jpsychires.2024.12.042_bib18","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/brain\/awab092","article-title":"To what degree is late life cognitive decline driven by age-related neuropathologies?","volume":"144","author":"Boyle","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.jpsychires.2024.12.042_bib20","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1017\/S0033291719001995","article-title":"An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis","volume":"49","author":"\u00c7akici","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2024.12.042_bib21","unstructured":"Carey, B., 2021. Science plays the long game, but people have mental health issues now. New York Times. April 6 2021 section D page 8."},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0893-133X(88)90012-7","article-title":"The current status of the dopamine hypothesis of schizophrenia","volume":"1","author":"Carlsson","year":"1988","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/schbul\/16.3.425","article-title":"Schizophrenia: a subcortical neurotransmitter imbalance syndrome?","volume":"16","author":"Carlsson","year":"1990","journal-title":"Schizophr Bull"},{"issue":"7","key":"10.1016\/j.jpsychires.2024.12.042_bib24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0166-2236(90)90108-M","article-title":"Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease","volume":"13","author":"Carlsson","year":"1990","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib25","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.pharmtox.41.1.237","article-title":"Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence","volume":"41","author":"Carlsson","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.jpsychires.2024.12.042_bib26","first-page":"CD008016","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","volume":"8","author":"Ceraso","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.jpsychires.2024.12.042_bib27","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41386-021-00980-0","article-title":"Differentiating the effect of antipsychotic medication and illness on brain volume reductions in first-episode psychosis: a Longitudinal, Randomised, Triple-blind, Placebo-controlled MRI Study","volume":"46","author":"Chopra","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.jpsychires.2024.12.042_bib28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000477313","article-title":"Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy","volume":"86","author":"Chouinard","year":"2017","journal-title":"Psychother Psychosom"},{"issue":"2","key":"10.1016\/j.jpsychires.2024.12.042_bib29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/schbul\/sbx093","article-title":"N-acetylcysteine in a double-blind randomized placebo-controlled trial: toward biomarker-guided treatment in early psychosis","volume":"44","author":"Conus","year":"2018","journal-title":"Schizophr Bull"},{"issue":"4238","key":"10.1016\/j.jpsychires.2024.12.042_bib30","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.jpsychires.2024.12.042_bib31","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1073\/pnas.95.19.11406","article-title":"Hippocampal morphometry in schizophrenia by high dimensional brain mapping","volume":"95","author":"Csernansky","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.jpsychires.2024.12.042_bib32","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1176\/ajp.156.9.1328","article-title":"Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents","volume":"156","author":"Davidson","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"11","key":"10.1016\/j.jpsychires.2024.12.042_bib33","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1176\/ajp.148.11.1474","article-title":"Dopamine in schizophrenia: a review and reconceptualization","volume":"148","author":"Davis","year":"1991","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0925-4927(92)90009-S","article-title":"Increased prevalence of the cavum septum pellucidum in magnetic resonance scans and post-mortem brains of schizophrenic patients","volume":"45","author":"Degreef","year":"1992","journal-title":"Psychiatry Res"},{"issue":"6","key":"10.1016\/j.jpsychires.2024.12.042_bib35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0006-3223(94)00376-E","article-title":"A prospective follow-up study of brain morphology and cognition in first-episode schizophrenic patients: preliminary findings","volume":"38","author":"DeLisi","year":"1995","journal-title":"Biol Psychiatry"},{"issue":"10","key":"10.1016\/j.jpsychires.2024.12.042_bib36","first-page":"CD007906","article-title":"Intensive case management for severe mental illness","author":"Dieterich","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.jpsychires.2024.12.042_bib37","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1176\/appi.ps.201400281","article-title":"Implementing coordinated specialty care for early psychosis: the RAISE Connection Program","volume":"66","author":"Dixon","year":"2015","journal-title":"Psychiatr Serv"},{"issue":"9","key":"10.1016\/j.jpsychires.2024.12.042_bib38","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/sj.npp.1300710","article-title":"The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys","volume":"30","author":"Dorph-Petersen","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.jpsychires.2024.12.042_bib39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.yco.0000079209.36371.84","article-title":"Recent research on vocational rehabilitation for persons with severe mental illness","volume":"16","author":"Drake","year":"2003","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib40","series-title":"Individual Placement and Support: an Evidence-Based Approach to Supported Employment","author":"Drake","year":"2012"},{"issue":"7","key":"10.1016\/j.jpsychires.2024.12.042_bib41","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S2215-0366(20)30147-4","article-title":"Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: a longitudinal analysis and modelling study","volume":"7","author":"Drake","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.jpsychires.2024.12.042_bib42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ng1296","article-title":"Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia","volume":"36","author":"Emamian","year":"2004","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2012.02.030","article-title":"Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia","volume":"138","author":"Emsley","year":"2012","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib44","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/JCP.0b013e31827bfcc1","article-title":"Comparison of treatment response in second-episode versus first-episode schizophrenia","volume":"33","author":"Emsley","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-244X-13-50","article-title":"The nature of relapse in schizophrenia","volume":"13","author":"Emsley","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1016\/j.jpsychires.2024.12.042_bib46","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0022-3956(82)90038-3","article-title":"Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence?","volume":"17","author":"Feinberg","year":"1982","journal-title":"J Psychiatr Res"},{"issue":"4","key":"10.1016\/j.jpsychires.2024.12.042_bib47","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/schbul\/16.4.567","article-title":"Cortical pruning and the development of schizophrenia","volume":"16","author":"Feinberg","year":"1990","journal-title":"Schizophr Bull"},{"issue":"5","key":"10.1016\/j.jpsychires.2024.12.042_bib48","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/eip.12544","article-title":"Adjunctive nutrients in first-episode psychosis: a systematic review of efficacy, tolerability and neurobiological mechanisms","volume":"12","author":"Firth","year":"2018","journal-title":"Early Interv Psychiatry"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib49","series-title":"Four Inconvenient Truths of Mental Illness Treatment. 05\/06\/2014","year":"2014"},{"issue":"4","key":"10.1016\/j.jpsychires.2024.12.042_bib50","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/schbul\/sby125","article-title":"Oxidative stress and inflammation in first-episode psychosis: a systematic review and meta-analysis","volume":"45","author":"Fraguas","year":"2019","journal-title":"Schizophr Bull"},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib51","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/archgenpsychiatry.2011.1472","article-title":"Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk","volume":"69","author":"Fusar-Poli","year":"2012","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.jpsychires.2024.12.042_bib52","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1017\/S0033291701003312","article-title":"A cognitive model of the positive symptoms of psychosis","volume":"31","author":"Garety","year":"2001","journal-title":"Psychol Med"},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archpsyc.57.1.65","article-title":"Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia","volume":"57","author":"Glantz","year":"2000","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.jpsychires.2024.12.042_bib54","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pbb.2010.11.009","article-title":"The treatment of cognitive impairment in schizophrenia","volume":"99","author":"Goff","year":"2011","journal-title":"Pharmacology Biochemistry Behavior"},{"issue":"9","key":"10.1016\/j.jpsychires.2024.12.042_bib55","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1176\/appi.ajp.2017.16091016","article-title":"The long-term effects of antipsychotic medication on clinical course in schizophrenia","volume":"174","author":"Goff","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.jpsychires.2024.12.042_bib56","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamapsychiatry.2017.4595","article-title":"Association of hippocampal atrophy with duration of untreated psychosis and Molecular biomarkers during initial antipsychotic treatment of first-episode psychosis","volume":"75","author":"Goff","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.jpsychires.2024.12.042_bib57","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.schres.2008.11.003","article-title":"Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia","volume":"107","author":"Goldberg","year":"2009","journal-title":"Schizophr Res"},{"issue":"8","key":"10.1016\/j.jpsychires.2024.12.042_bib58","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nrn.2016.57","article-title":"Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression","volume":"17","author":"Grace","year":"2016","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"10.1016\/j.jpsychires.2024.12.042_bib59","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/archpsyc.55.2.145","article-title":"A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures","volume":"55","author":"Gur","year":"1998","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"10.1016\/j.jpsychires.2024.12.042_bib60","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/2045125318781475","article-title":"The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses","volume":"8","author":"Haddad","year":"2018","journal-title":"Ther Adv Psychopharmacol"},{"issue":"5","key":"10.1016\/j.jpsychires.2024.12.042_bib61","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/schbul\/sbs118","article-title":"Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects","volume":"39","author":"Haijma","year":"2013","journal-title":"Schizophr Bull"},{"issue":"Suppl. 2","key":"10.1016\/j.jpsychires.2024.12.042_bib62","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4088\/JCP.13065su1.08","article-title":"What is the evidence for changes in cognition and functioning over the lifespan in patients with schizophrenia?","volume":"75","author":"Harvey","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.jpsychires.2024.12.042_bib63","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/hipo.1068","article-title":"Neuroimaging studies of the hippocampus in schizophrenia","volume":"11","author":"Heckers","year":"2001","journal-title":"Hippocampus"},{"issue":"5","key":"10.1016\/j.jpsychires.2024.12.042_bib64","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/YIC.0b013e3280c28424","article-title":"The attitude of patients towards antipsychotic depot treatment","volume":"22","author":"Heres","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.jpsychires.2024.12.042_bib65","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/archpsyc.1991.01810280049007","article-title":"Intermittent vs maintenance medication in schizophrenia. Two-year results","volume":"48","author":"Herz","year":"1991","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib66","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/oxfordjournals.schbul.a007023","article-title":"Global intellectual impairment does not accelerate with age in patients with schizophrenia: a cross-sectional analysis","volume":"29","author":"Hijman","year":"2003","journal-title":"Schizophr Bull"},{"issue":"9","key":"10.1016\/j.jpsychires.2024.12.042_bib67","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1176\/ajp.156.9.1336","article-title":"Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia","volume":"156","author":"Hoff","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib68","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/schbul\/21.3.379","article-title":"Personal therapy: a disorder-relevant psychotherapy for schizophrenia","volume":"21","author":"Hogarty","year":"1995","journal-title":"Schizophr Bull"},{"issue":"4","key":"10.1016\/j.jpsychires.2024.12.042_bib69","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1192\/bjp.164.4.494","article-title":"Is there cognitive decline in schizophrenia? A cross-sectional study","volume":"164","author":"Hyde","year":"1994","journal-title":"Br J Psychiatry"},{"issue":"6","key":"10.1016\/j.jpsychires.2024.12.042_bib70","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/schbul\/sbq057","article-title":"Neuropsychological performance in older patients with schizophrenia: a meta-analysis of cross-sectional and longitudinal studies","volume":"37","author":"Irani","year":"2011","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib71","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djab131","article-title":"Annual report to the nation on the status of cancer, Part 1: national cancer statistics","author":"Islami","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.jpsychires.2024.12.042_bib72","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib73","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fnins.2013.00110","article-title":"Perinatal complications and schizophrenia: involvement of the immune system","volume":"7","author":"Jenkins","year":"2013","journal-title":"Front Neurosci"},{"issue":"6756","key":"10.1016\/j.jpsychires.2024.12.042_bib74","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/bmj.301.6756.837","article-title":"Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years","volume":"301","author":"Jolley","year":"1990","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jpsychires.2024.12.042_bib75","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2217\/cer-2017-0043","article-title":"Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits","volume":"7","author":"Joshi","year":"2018","journal-title":"J Comp Eff Res"},{"issue":"Suppl. 14","key":"10.1016\/j.jpsychires.2024.12.042_bib76","first-page":"27","article-title":"Treatment strategies to prevent relapse and encourage remission","volume":"68","author":"Kane","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib77","doi-asserted-by":"crossref","first-page":"18m12546","DOI":"10.4088\/JCP.18m12546","article-title":"Patients with early-phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable antipsychotics): results from the recruitment phase of the PRELAPSE trial","volume":"80","author":"Kane","year":"2019","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"10.1016\/j.jpsychires.2024.12.042_bib78","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2020.2076","article-title":"Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial","volume":"77","author":"Kane","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib79","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/schbul\/sbaa177","article-title":"Kraepelin's final views on dementia praecox","volume":"47","author":"Kendler","year":"2021","journal-title":"Schizophr Bull"},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib80","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/schbul\/sbx090","article-title":"Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies","volume":"44","author":"Kishimoto","year":"2018","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib81","series-title":"Dementia Praecox and Paraphrenia","author":"Kraepelin","year":"1919"},{"issue":"8","key":"10.1016\/j.jpsychires.2024.12.042_bib82","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/jamapsychiatry.2015.0712","article-title":"Association of IQ changes and progressive brain changes in patients with schizophrenia","volume":"72","author":"Kubota","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib83","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0006-3223(99)00067-0","article-title":"Increased dopamine transmission in schizophrenia: relationship to illness phases","volume":"46","author":"Laruelle","year":"1999","journal-title":"Biol Psychiatry"},{"issue":"6","key":"10.1016\/j.jpsychires.2024.12.042_bib84","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1192\/bjp.bp.115.179895","article-title":"Rethinking funding priorities in mental health research","volume":"208","author":"Lewis-Fern\u00e1ndez","year":"2016","journal-title":"Br J Psychiatry"},{"issue":"2","key":"10.1016\/j.jpsychires.2024.12.042_bib85","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/01454455840082002","article-title":"Social skills training with relapsing schizophrenics. An experimental analysis","volume":"8","author":"Liberman","year":"1984","journal-title":"Behav Modif"},{"issue":"6","key":"10.1016\/j.jpsychires.2024.12.042_bib86","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0006-3223(99)00147-X","article-title":"Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective","volume":"46","author":"Lieberman","year":"1999","journal-title":"Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.jpsychires.2024.12.042_bib87","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20543","article-title":"Disease modifying effects of antipsychotic drugs in schizophrenia: a clinical and neurobiological perspective","volume":"17","author":"Lieberman","year":"2018","journal-title":"World Psychiatry"},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib88","first-page":"92","article-title":"Treatment outcome of first episode schizophrenia","volume":"25","author":"Lieberman","year":"1989","journal-title":"Psychopharmacol Bull"},{"issue":"5","key":"10.1016\/j.jpsychires.2024.12.042_bib89","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archpsyc.1993.01820170047006","article-title":"Time course and biologic correlates of treatment response in first-episode schizophrenia","volume":"50","author":"Lieberman","year":"1993","journal-title":"Arch Gen Psychiatry"},{"issue":"3 Suppl. l","key":"10.1016\/j.jpsychires.2024.12.042_bib90","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/0893-133X(95)00200-W","article-title":"Psychobiologic correlates of treatment response in schizophrenia","volume":"14","author":"Lieberman","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.jpsychires.2024.12.042_bib91","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0893-133X(97)00045-6","article-title":"Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity","volume":"17","author":"Lieberman","year":"1997","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.jpsychires.2024.12.042_bib92","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0006-3223(01)01303-8","article-title":"The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches","volume":"50","author":"Lieberman","year":"2001","journal-title":"Biol Psychiatry"},{"issue":"8","key":"10.1016\/j.jpsychires.2024.12.042_bib93","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1038\/mp.2017.249","article-title":"Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention","volume":"23","author":"Lieberman","year":"2018","journal-title":"Mol Psychiatry"},{"issue":"10","key":"10.1016\/j.jpsychires.2024.12.042_bib94","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1176\/appi.ajp.2019.19080865","article-title":"Early detection and preventive intervention in schizophrenia: from fantasy to reality","volume":"176","author":"Lieberman","year":"2019","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.jpsychires.2024.12.042_bib95","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tins.2008.02.005","article-title":"Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia","volume":"31","author":"Lisman","year":"2008","journal-title":"Trends Neurosci"},{"issue":"42","key":"10.1016\/j.jpsychires.2024.12.042_bib96","doi-asserted-by":"crossref","first-page":"11424","DOI":"10.1523\/JNEUROSCI.2847-07.2007","article-title":"Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia","volume":"27","author":"Lodge","year":"2007","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib97","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41598-019-57340-8","article-title":"Lithium for schizophrenia: supporting evidence from a 12-year, nationwide health insurance database and from Akt1-deficient mouse and cellular models","volume":"10","author":"Luo","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib98","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2010.09.021","article-title":"Duration of untreated psychosis is associated with orbital-frontal grey matter volume reductions in first episode psychosis","volume":"125","author":"Malla","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib99","first-page":"1163","article-title":"Clinical pharmacology of atypical antipsychotics: an update","volume":"13","author":"Mauri","year":"2014","journal-title":"EXCLI J"},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","article-title":"Schizophrenia, dopamine and the striatum: from biology to symptoms","volume":"42","author":"McCutcheon","year":"2019","journal-title":"Trends Neurosci"},{"issue":"4","key":"10.1016\/j.jpsychires.2024.12.042_bib101","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/schbul\/sbl032","article-title":"Is active psychosis neurotoxic?","volume":"32","author":"McGlashan","year":"2006","journal-title":"Schizophr Bull"},{"issue":"4","key":"10.1016\/j.jpsychires.2024.12.042_bib102","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/oxfordjournals.schbul.a007046","article-title":"The \"close-in\" or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder","volume":"29","author":"McGorry","year":"2003","journal-title":"Schizophr Bull"},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib103","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/jamapsychiatry.2016.2902","article-title":"Effect of omega-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial","volume":"74","author":"McGorry","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib104","series-title":"Cognitive Remediation for Psychological DisordersTherapist Guide: Therapist Guide","author":"Medalia","year":"2017"},{"issue":"2","key":"10.1016\/j.jpsychires.2024.12.042_bib105","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/CIRCRESAHA.116.309115","article-title":"Decline in cardiovascular mortality: possible causes and implications","volume":"120","author":"Mensah","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib106","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"12","author":"Miyamoto","year":"2012","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib107","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Molecular Psychiatry"},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib109","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1037\/0022-006X.72.3.479","article-title":"The Hartford study of supported employment for persons with severe mental illness","volume":"72","author":"Mueser","year":"2004","journal-title":"J Consult Clin Psychol"},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib110","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/157339510791823673","article-title":"Immune system and schizophrenia","volume":"6","author":"Muller","year":"2010","journal-title":"Curr Immunol Rev"},{"issue":"6600","key":"10.1016\/j.jpsychires.2024.12.042_bib111","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/bmj.295.6600.681","article-title":"Is schizophrenia a neurodevelopmental disorder?","volume":"295","author":"Murray","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"2","key":"10.1016\/j.jpsychires.2024.12.042_bib112","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/schbul\/18.2.319","article-title":"A neurodevelopmental approach to the classification of schizophrenia","volume":"18","author":"Murray","year":"1992","journal-title":"Schizophr Bull"},{"issue":"4","key":"10.1016\/j.jpsychires.2024.12.042_bib113","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/schbul\/21.4.527","article-title":"Prodromal symptoms of relapse in schizophrenia: a review","volume":"21","author":"Norman","year":"1995","journal-title":"Schizophr Bull"},{"issue":"6","key":"10.1016\/j.jpsychires.2024.12.042_bib114","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/schbul\/sbx166","article-title":"Can we reduce the duration of untreated psychosis? A systematic review and meta-analysis of controlled interventional studies","volume":"44","author":"Oliver","year":"2018","journal-title":"Schizophr Bull"},{"issue":"10","key":"10.1016\/j.jpsychires.2024.12.042_bib115","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/0269881109104882","article-title":"Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years","volume":"24","author":"Patel","year":"2010","journal-title":"J Psychopharmacol"},{"issue":"9","key":"10.1016\/j.jpsychires.2024.12.042_bib116","first-page":"638","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel","year":"2014","journal-title":"P T"},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib117","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12888-020-02530-2","article-title":"Attitudes of European physicians towards the use of long-acting injectable antipsychotics","volume":"20","author":"Patel","year":"2020","journal-title":"BMC Psychiatry"},{"issue":"10","key":"10.1016\/j.jpsychires.2024.12.042_bib118","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1176\/appi.ajp.162.10.1785","article-title":"Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis","volume":"162","author":"Perkins","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib119","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.schres.2018.10.013","article-title":"Changes in insight over the first 24 months of treatment in schizophrenia spectrum disorders","volume":"206","author":"Phahladira","year":"2019","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib120","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/PPA.S127623","article-title":"Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic","volume":"11","author":"Pilon","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"10.1016\/j.jpsychires.2024.12.042_bib121","first-page":"185","article-title":"Neurodevelopment or neurodegeneration: review of theories of schizophrenia","volume":"42","author":"Pino","year":"2014","journal-title":"Actas Esp Psiquiatr"},{"issue":"2","key":"10.1016\/j.jpsychires.2024.12.042_bib122","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3109\/13651501.2016.1149195","article-title":"Clinical factors related to schizophrenia relapse","volume":"20","author":"Porcelli","year":"2016","journal-title":"Int J Psychiatry Clin Pract"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib123","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1471-244X-13-261","article-title":"Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia","volume":"13","author":"Potkin","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"5768","key":"10.1016\/j.jpsychires.2024.12.042_bib125","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/286074a0","article-title":"Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats","volume":"286","author":"Pycock","year":"1980","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jpsychires.2024.12.042_bib126","first-page":"292","article-title":"Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications","volume":"4","author":"Riordan","year":"2011","journal-title":"Am Health Drug Benefits"},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib127","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","article-title":"Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder","volume":"56","author":"Robinson","year":"1999","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib128","first-page":"87","article-title":"Neurocognition and duration of psychosis: a 10-year follow-up of first-episode patients","volume":"42","author":"Rund","year":"2016","journal-title":"Schizophr Bull"},{"issue":"22","key":"10.1016\/j.jpsychires.2024.12.042_bib129","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa0806142","article-title":"Age, neuropathology, and dementia","volume":"360","author":"Savva","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jpsychires.2024.12.042_bib130","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1001\/archpsyc.1994.03950020048005","article-title":"Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia","volume":"51","author":"Saykin","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib131","series-title":"Schizophrenia & Psychosis Action Alliance: Societal Costs of Schizophrenis & Related Disorders","year":"2021"},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib132","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neuron.2013.02.011","article-title":"Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver","volume":"78","author":"Schobel","year":"2013","journal-title":"Neuron"},{"issue":"1\u20133","key":"10.1016\/j.jpsychires.2024.12.042_bib133","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.schres.2015.08.015","article-title":"Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia","volume":"169","author":"Schreiner","year":"2015","journal-title":"Schizophr Res"},{"issue":"7589","key":"10.1016\/j.jpsychires.2024.12.042_bib134","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature16549","article-title":"Schizophrenia risk from complex variation of complement component 4","volume":"530","author":"Sekar","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0006-3223(98)00281-9","article-title":"The reduced neuropil hypothesis: a circuit based model of schizophrenia","volume":"45","author":"Selemon","year":"1999","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib136","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41593-018-0334-7","article-title":"Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning","volume":"22","author":"Sellgren","year":"2019","journal-title":"Nat Neurosci"},{"issue":"7\u20138","key":"10.1016\/j.jpsychires.2024.12.042_bib137","first-page":"17","article-title":"Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents","volume":"9","author":"Sheehan","year":"2012","journal-title":"Innov Clin Neurosci"},{"issue":"3\u20134","key":"10.1016\/j.jpsychires.2024.12.042_bib138","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0022-3956(97)00052-6","article-title":"The natural history and pathophysiology of treatment resistant schizophrenia","volume":"32","author":"Sheitman","year":"1998","journal-title":"J Psychiatr Res"},{"issue":"11","key":"10.1016\/j.jpsychires.2024.12.042_bib139","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/jamapsychiatry.2020.1619","article-title":"Association between the duration of untreated psychosis and selective cognitive performance in community-dwelling individuals with chronic untreated schizophrenia in rural China","volume":"77","author":"Stone","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.jpsychires.2024.12.042_bib140","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","article-title":"Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of Schizophrenia. A randomized clinical trial","volume":"72","author":"Subotnik","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"10.1016\/j.jpsychires.2024.12.042_bib141","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJM199003223221201","article-title":"Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia","volume":"322","author":"Suddath","year":"1990","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jpsychires.2024.12.042_bib142","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1192\/bjp.bp.106.029009","article-title":"Longitudinal studies of cognition in schizophrenia: meta-analysis","volume":"192","author":"Szoke","year":"2008","journal-title":"Br J Psychiatry"},{"issue":"6","key":"10.1016\/j.jpsychires.2024.12.042_bib143","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/schbul\/sbx176","article-title":"Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-a nationwide study with 20-year follow-up","volume":"44","author":"Taipale","year":"2018","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib144","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.schres.2017.12.010","article-title":"Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia","volume":"197","author":"Taipale","year":"2018","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"issue":"6","key":"10.1016\/j.jpsychires.2024.12.042_bib146","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41386-018-0278-3","article-title":"Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia","volume":"44","author":"Takeuchi","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib147","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/BF01435740","article-title":"Stein LI: practical guidelines for the community treatment of markedly impaired patients","volume":"12","author":"Test","year":"1976","journal-title":"Community Ment Health J"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib148","series-title":"Ten Years that Changed the Face of Mental Illness","author":"Thuillier","year":"1999"},{"issue":"5","key":"10.1016\/j.jpsychires.2024.12.042_bib149","first-page":"454","article-title":"Abnormal trajectory of intracortical myelination in schizophrenia implicates white matter in disease pathophysiology and the therapeutic mechanism of action of antipsychotics","volume":"3","author":"Tishler","year":"2018","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib150","unstructured":"Torrey E., Lieberman J: The Underuse of Clozapine and Long-Acting Injectable Antipsychotics; Psychiatric Services on line in advance https:\/\/doi.org\/10.1176\/appi.ps.202401."},{"issue":"11","key":"10.1016\/j.jpsychires.2024.12.042_bib151","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241062","article-title":"Using the NIH research, condition and disease categorization database for research advocacy: schizophrenia research at NIMH as an example","volume":"15","author":"Torrey","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jpsychires.2024.12.042_bib152","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.biopsych.2004.06.026","article-title":"The relationship between volumetric brain changes and cognitive function: a family study on schizophrenia","volume":"56","author":"Toulopoulou","year":"2004","journal-title":"Biol Psychiatry"},{"issue":"10","key":"10.1016\/j.jpsychires.2024.12.042_bib153","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/sj.npp.1301347","article-title":"Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study","volume":"32","author":"van Haren","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.jpsychires.2024.12.042_bib154","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/archgenpsychiatry.2011.88","article-title":"Changes in cortical thickness during the course of illness in schizophrenia","volume":"68","author":"van Haren","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jpsychires.2024.12.042_bib155","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1192\/bjp.179.4.300","article-title":"Systematic review of patient and nurse attitudes to depot antipsychotic medication","volume":"179","author":"Walburn","year":"2001","journal-title":"Br J Psychiatry"},{"issue":"7","key":"10.1016\/j.jpsychires.2024.12.042_bib156","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archpsyc.1987.01800190080012","article-title":"Implications of normal brain development for the pathogenesis of schizophrenia","volume":"44","author":"Weinberger","year":"1987","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib157","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.biopsych.2016.03.2104","article-title":"Pathway-specific dopamine abnormalities in schizophrenia","volume":"81","author":"Weinstein","year":"2017","journal-title":"Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.jpsychires.2024.12.042_bib158","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a033315","article-title":"Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort","volume":"24","author":"Wiersma","year":"1998","journal-title":"Schizophr Bull"},{"issue":"8","key":"10.1016\/j.jpsychires.2024.12.042_bib159","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.euroneuro.2012.09.008","article-title":"Glycine treatment of the risk syndrome for psychosis: report of two pilot studies","volume":"23","author":"Woods","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.jpsychires.2024.12.042_bib160","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0920-9964(91)90073-Z","article-title":"Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia","volume":"5","author":"Wyatt","year":"1991","journal-title":"Schizophr Res"},{"issue":"2","key":"10.1016\/j.jpsychires.2024.12.042_bib161","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41593-020-00763-8","article-title":"Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice","volume":"24","author":"Yilmaz","year":"2021","journal-title":"Nat Neurosci"},{"issue":"10","key":"10.1016\/j.jpsychires.2024.12.042_bib162","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1176\/appi.ajp.2019.18091088","article-title":"Cognitive change in schizophrenia and other psychoses in the decade following the first episode","volume":"176","author":"Zanelli","year":"2019","journal-title":"Am J Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.jpsychires.2024.12.042_bib163","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.schres.2013.08.001","article-title":"Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review","volume":"152","author":"Zipursky","year":"2014","journal-title":"Schizophr Res"},{"issue":"51","key":"10.1016\/j.jpsychires.2024.12.042_bib164","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112560118","article-title":"High-impact rare genetic variants in severe schizophrenia","volume":"118","author":"Zoghbi","year":"2021","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395624007441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395624007441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:37:16Z","timestamp":1762209436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395624007441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":162,"alternative-id":["S0022395624007441"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2024.12.042","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preventing disease progression in schizophrenia: What are we waiting for","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2024.12.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}